CVE-2020-10627Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an…
- 7.3HighCVSS base score
- 0.49%Exploitation in 30 daysEPSS · top 57% of all CVEs
- NoKnown exploitednot in CISA's KEV catalog
- NonePublic exploitsnone known yet
Description
Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.
Timeline
ID reserved
By icscert
- 21 months later
· 21 months later
Published
- 3 years later
· 3 years later
Record updated
Changes after publication (a new score, a public exploit, EPSS crossing 1, 10 or 50 %, leaving KEV) are kept since November 2026; earlier ones are not known.
Scores
| Scored by | CVSS | Score | Vector |
|---|---|---|---|
| icscertCNA (assigner) | 3.1 | High7.3 | CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:L |
| NVDNVD · Modified | 3.1 | High8.1 | CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N |
- EPSS (exploitation in 30 days)
- 0.49% · top 57% of all CVEs (19 Nov 2026)
The list uses the assigner's score when there is one, then CISA's, then NVD's: High 7.3.
Affected products
Insulet · Omnipod Insulin Management System
- affected 19191
- affected 40160
- affected ZXP425
- affected ZXR425
What to do
Workaround: Insulet recommends patients using the affected products talk to their healthcare provider about the risks of continued use, including the possibility of changing to the latest model with increased cybersecurity protection. Additionally, Insulet recommends all patients take the cybersecurity precautions indicated below. Do not connect to or allow any third-party devices to be connected to or use any software not authorized by Insulet. Maintain tight physical control of the pump and devices connected to the pump. Be attentive to pump notifications, alarms, and alerts. Immediately cancel any unintended boluses (a single dose of insulin administered all at once). Monitor blood glucose levels closely and act as appropriate. Get medical help immediately when experiencing symptoms of severe hypoglycemia or diabetic ketoacidosis or if you suspect insulin pump settings or insulin delivery has changed unexpectedly. Insulet has released additional patient-focused information: https://www.myomnipod.com/security-bulletins More information is available regarding Insulet’s product security and vulnerability management: https://www.myomnipod.com/product-security
References
References2
- https://us-cert.cisa.gov/ics/advisories/icsma-20-079-01 (opens in a new tab)x_refsource_MISCx_transferred
- https://www.myomnipod.com/security-bulletins (opens in a new tab)x_refsource_MISCx_transferred
Sources
The same CVE in the primary databases and aggregators, to check against.
- CVE.org record (opens in a new tab)
- CVE List JSON (GitHub) (opens in a new tab)
- NVD (opens in a new tab)
- FIRST EPSS (opens in a new tab)
- EUVD EUVD-2020-3075 (opens in a new tab)
- OSV.dev (opens in a new tab)
- GitHub Advisories (opens in a new tab)
- CIRCL Vulnerability-Lookup (opens in a new tab)
Badge for a README or a ticket
[](https://cveledger.app/cve/CVE-2020-10627)Record last updated .